Thyroxine Sodium (Levothyroxine Sodium) Tablets BP/ IP

1. Product Introduction

Thyroxine Sodium, also known as Levothyroxine Sodium, is a synthetic form of the naturally occurring thyroid hormone thyroxine (T4). It is used as replacement therapy in patients whose thyroid gland does not produce enough thyroid hormone.

Healthy Life Pharma Pvt. Ltd. provides B2B manufacturing and supply support for levothyroxine sodium tablets. Because levothyroxine is dosed in micrograms and has a narrow therapeutic window, accurate weighing, blend uniformity, tablet-to-tablet content uniformity and stability controls are especially important.

The supplied product labels confirm uncoated BP/IP tablets at 25 mcg, 50 mcg, 100 mcg (0.1 mg) and 250 mcg (0.25 mg). Other strengths should be listed only after confirmation against the relevant approved master formula and market registration.

2. Product Specifications

Note: 0.1 mg equals 100 mcg, and 0.25 mg equals 250 mcg. The 250 mcg strength is included because it appears in the supplied label text; market availability and registration should be verified before commercial publication.

3. Manufacturing Considerations

Levothyroxine is a microgram-dose medicine, so manufacturing controls must focus on dose accuracy and stability.

• Blend and content uniformity: validated dispensing and blending processes are required to distribute the low-dose active ingredient consistently throughout the batch.
• In-process control: tablet weight, compression parameters and sampling plans should be appropriate for a narrow-therapeutic-index product.
• Environmental and handling controls: processing conditions should be defined from stability and compatibility studies for the actual formulation rather than assumed from a generic process.
• Packaging: the final container-closure system should protect the product from environmental conditions shown to affect stability, according to the approved dossier.

Claims regarding particular granulation technologies, desiccants, cold-chain shipping, humidity limits or dedicated packaging should be made only when they match validated manufacturing and stability documentation.

4. Quality Assurance

Finished-product testing should follow the registered specification and applicable BP/IP requirements. Typical controls may include:

• Identification and assay of levothyroxine using validated analytical methods.
• Uniformity of dosage units / content uniformity, which is particularly important for microgram-dose tablets.
• Dissolution or drug-release testing according to the approved monograph or product specification.
• Related substances / degradation-product testing and stability-indicating methods.
• Physical tests such as appearance, average weight, hardness or friability where applicable.
• Long-term and accelerated stability studies in the proposed commercial packaging.

Specific assay limits, dissolution criteria and shelf life must come from the registered specification rather than a generic numerical claim.

5. Why Levothyroxine Is Used

Levothyroxine is synthetic thyroxine (T4). After administration, some T4 is converted in the body to triiodothyronine (T3), and thyroid hormones help regulate metabolism, growth, cardiovascular function and many other physiological processes.

• Hypothyroidism: replacement of deficient thyroid hormone is the principal use.
• Selected thyroid conditions: levothyroxine may also be used for TSH suppression in certain thyroid-cancer settings under specialist supervision.

It should not be promoted as a general weight-loss medicine. Excess thyroid hormone can cause serious cardiovascular and other adverse effects.

6. Export and Regulatory Support

B2B registration and export support may include technical documentation and commercial paperwork depending on the destination market, licensing status and contractual scope.

• Product specifications, COA formats and stability documentation where available.
• CTD / ACTD dossier support when prepared and approved for the relevant product.
• FSC, COPP, WHO-GMP or other certificates only when currently valid and applicable.
• Shipping and pack configurations according to approved storage conditions and importing-country requirements.

7. Frequently Asked Questions

Q: What strengths are confirmed in the supplied product information?
A: 25 mcg, 50 mcg, 100 mcg (0.1 mg) and 250 mcg (0.25 mg) are explicitly stated in the supplied label text.

Q: Are Thyroxine Sodium and Levothyroxine Sodium the same medicine?
A: Levothyroxine is the synthetic form of thyroxine (T4); product labels commonly use the terms levothyroxine sodium or thyroxine sodium.

Q: Why are levothyroxine strengths expressed in micrograms?
A: The medicine is potent at very small doses, and patients often require individualized titration based on thyroid-function tests and clinical factors.

Q: Can a patient switch strength or brand without monitoring?
A: Dose changes and product switches should be managed with appropriate clinical follow-up because relatively small changes in exposure can affect thyroid control.

8. Dosage and Administration

Levothyroxine dosing must be individualized by a qualified healthcare professional using thyroid-function tests, age, body weight, cardiovascular status, pregnancy status and other clinical factors.

• It is commonly taken consistently on an empty stomach, often 30–60 minutes before breakfast, unless the approved local label directs otherwise.
• Consistency in relation to meals is important because food can affect absorption.
• Calcium, iron, antacids and several other medicines or supplements can reduce absorption; separation intervals should follow the prescribing information or clinician's advice.
• Do not change dose, strength or brand solely on the basis of symptoms without clinical review and thyroid-function testing.

9. Side Effects and Precautions

Adverse effects often reflect excessive thyroid-hormone exposure rather than an inherent effect at an appropriate replacement dose.

• Excess dose: palpitations, fast or irregular heartbeat, tremor, nervousness, sweating, heat intolerance, insomnia or unexplained weight loss may occur.
• Cardiovascular disease and older adults: cautious initiation and titration may be required.
• Pregnancy: thyroid-hormone requirements can change; patients should not stop treatment on their own and should receive appropriate monitoring.
• Drug/food interactions: calcium, iron, certain antacids, bile-acid sequestrants and some foods can alter absorption. Follow the approved prescribing information.
• Not for weight loss: thyroid hormones should not be used for obesity treatment in euthyroid individuals.

Seek medical advice for symptoms suggesting over-replacement, under-replacement or a significant adverse reaction.

10. Storage Instructions

• Store according to the approved product label and registered stability conditions.
• Protect from excessive heat, moisture and light as specified for the final commercial pack.
• Keep in the original container or blister until use.
• Keep out of reach of children.